ProQR Therapeutics N.V. (PRQR): Jennison Associates Grabbed A Large Chunk Of This Biotech Stock

ProQR Therapeutics N.V. (NASDAQ:PRQR) is a tiny $134 million company with a daily trading volume of only $500 thousand. Yet, it managed to attract a 11.5% investment from Jennison Associates recently. Jennison isn’t the only healthcare investor with a large ProQR Therapeutics position either. Samuel Isaly’s OrbiMed had $20 million invested in the stock at the end of December. Another healthcare heavyweight, Baker Brothers, had nearly $9 million riding on this biotech stock. Even billionaires Israel Englander and Andreas Halvorsen have relatively large positions in the stock.

Overall, hedge funds tracked by Insider Monkey owned a quarter of ProQR Therapeutics’ shares at the end of December. Jennison’s new position is as of March 31st. The details of its filing can be found below:

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Jennison Associates 2,674,844 0 0 2,674,844 2,674,844 11.5%

Page 1 of 5 – SEC Filing

Securities and Exchange Commission

Washington, D.C. 20549

Schedule 13G

Under the Securities Exchange Act of 1934

(Amendment No. 0)*

March 31, 2016
(Date of event which requires filing of this statement)

Check the appropriate box to designate the rule pursuant to which

this schedule is filed:

(X) Rule 13d-1(b)

( ) Rule 13d-1(c)

( ) Rule 13d-1(d)

Name of Issuer: ProQR Therapeutics N.V.

Title of Class of Securities: Ordinary Shares

CUSIP Number: N71542109

*The remainder of this cover page shall be filled out for a

reporting person’s initial filing on this form with respect to

the subject class of securities, and for any subsequent

amendment containing information which would alter the

disclosures provided in a prior cover page.

The information required in the remainder of this cover page

shall not be deemed to be “filed” for the purpose of Section 18

of the Securities Exchange Act of 1934 (“Act”) or otherwise

subject to the liabilities of that section of the Act but shall

be subject to all other provisions of the Act (however, see the


Follow Proqr Therapeutics N.v. (NASDAQ:PRQR)